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INTRODUCTION 
Parkinson’s disease (PD)1 is a chronic neurodegenerative progressive 
neurological disease  with clinical features viz rigidity, bradykinesia, rest 
tremor and postural instability. Assymetry is a prominent feature of this 
disease. PD ranks second among the common neurodegenerative disease 
next only to Alzheimer’s dementia. 
The pathological characteristic of PD is intraneuronal alpha synuclein 
positive Lewy bodies and loss of neuronal cell. Apart from classical motor 
symptoms PD patients also develop non motor symptoms. Non motor 
symptoms cause a major disability in PD and the prominently contribute to 
decreasing quality of life especially in advanced stages of disease. The 
major non motor symptoms are olfactory loss, psychiatric disturbances of 
depression and anxiety, sleep disorders,  cognitive dysfunction, and chiefly 
the Autonomic Dysfunction. 
Autonomic symptoms in Parkinson’s disease (PD) were first reported in 
1817 by James Parkinson himself. He described abnormalities of salivation 
and sweating, and dysfunction of the alimentary tract and urinary bladder. 
Patients rarely volunteer symptoms of autonomic disturbance in clinic, and 
perhaps because of this, there has been little interest in autonomic 
dysfunction in PD until recent years. Demonstration of the importance of 
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dysautonomia in Parkinsonism patients, led to a  recent resurgence in this 
area. The introduction of standardised diagnostic criteria for PD has 
improved diagnostic accuracy, and reports since the introduction of these 
guidelines continue to suggest that between 50% and 80% of subjects have 
objective evidence of autonomic involvement 
 Autonomic nervous system disturbances are seen in advanced PD 
but are not as early or severe as in Multiple System Atrophy1,17,19. 
Dysphagia may be prominent in some patients with severe PD when it is 
usually accompanied by marked dysarthria. Some patients develop urinary 
frequency and urgency by day as well as nocturia. Postural hypotension1 is 
the most common manifestation but it may be difficult to assess the 
relative contributions of the disease and medications, especially dopamine 
agonists. The fall in blood pressure is severe or disabling in idiopathic 
Parkinson's disease. Impotence is frequently reported and is probably 
secondary to autonomic involvement, depression, and physical immobility, 
especially at night. Constipation1 is very common in Parkinson's disease at 
most stages of the condition and is sometimes severe, requiring hospital 
admission. Though there are several factors underlying this like reduced 
exercise, dietary changes, and the effects of anticholinergic drugs, 
dysautonomia chiefly contribute to the cause. Many patients notice 
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increased sweating; in the later stages of the condition, especially in severe 
off periods in levodopa treated patients, there may attacks of drenching 
sweating with immobility, fear, and often pain. Thus autonomic symptoms 
include reduced gastrointestinal tract motility with postprandial bloating, 
constipation, urinary problems, sexual problems, disordered sweating, and 
orthostatic hypotension. The advances in management of this autonomic 
symptoms stresses the need for identification of autonomic symptoms 
early and improve the quality of life.  
Hence we have undertaken this study to assess the autonomic 
dysfunction  in PD, their prevalence, early identification and clinical 
testing, so as to diagnose early autonomic dysfunction, in order that 
suitable treatment may be initiated to  improve quality of life.  
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AIMS OF THE STUDY 
The main aims of the study  
1. To evaluate the prevalence of autonomic nervous system 
dysfunction in Parkinsons’s disease 
2. To assess the prevalence and the impact Of Age, Sex, Duration of  
PD on  severity of Autonomic Dysfunction  
3. To Assess The Correlation Of  Hoehn And Yahr  Staging of  
Parkinson’s Disease And Autonomic  Dysfunction 
4. To correlate the  prevalence  of  Cardiovascular Autonomic Nervous 
System dysfunction in PD patients based on basic  cardiovascular  
autonomic function tests with that of staging. 
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REVIEW OF LITERATURE 
Autonomic nervous system(ANS)  is broadly classified into sympathetic 
and parasympathetic  system1. The sympathetic system is also known as 
thoracolumbar “outflow”, because  the neurons start in the thoracolumbar         
(T1-L2) regions of the spinal cord1. The parasympathetic system is also 
known as  “craniosacral outflow”, because  the neurons start mainly from 
the cranial nerves (CN III, CN VII, CN IX, CN X) and sacral (S2,S3,S4) 
segments of spinal cord. There is a third system called enteric nervous 
system. 
The ANS is has two sets of neuron viz preganglionic neuron that initially 
synapse with the postganglionic neuron and then synapsing with  target 
organ.  
Sympathetic system 
The sympathetic nervous system  (thoracolumbar outflow)1  preganglionic 
fibres arise from cells located in the  (intermediolateral cell columns from 
T1 to L2 segments of spinal cord. The  preganglionic neurons  synapse for 
their postganglionic neurons at the following locations. 
Paravertebral ganglia belonging to the sympathetic chain are present on 
both sides of the vertebra. 
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Prevertebral ganglia consisting of celiac ganglion, aorticorenal ganglion, 
superior and inferior mesenteric ganglion, aorticorenal ganglion. 
Adrenal  medulla Chromaffin cells  synapse directly onto the target cell. 
Parasympathetic system1 
Craniosacral  outflow1 arise from the following two regions: 
1. Cranial Nerves III, VII, IX, X 
2. Sacral  segments of spinal cord S2, S3, S4.  
 
In the sympathetic system, the preganglionic fibres are relatively short, 
myelinated and cholinergic whereas the postganglionic fibres are long. 
unmyelinated, primarily adrenergic with the exception of cholinergic sweat 
glands. In  the parasympathetic system the preganglionic fibres are long 
and postganglionic fibres are short and cholinergic. These two systems 
modulates vital functions, in  antagonistic way only to maintain 
homeostasis. Following are  actions of the sympathetic and the  
parasympathetic system 
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Sympathetic nervous system 
x Diversion of  blood flow  to vital organs and restriction of  flow to 
gastrointestinal system and skin by and restriction of  flow to by 
vasoconstriction. 
x Blood flow to skeletal muscles and the lungs are enhanced  
x Bronchodilation 
x Increases heart rate and blood pressure and the contractility of heart 
cells  
x Pupillary dilation and relaxation of the ciliary muscle to the lens which 
allows entry of more light to eye and farther vision. 
x Coronary Vasodilation. 
x Constriction of  both intestinal and  urinary sphincter. 
x Inhibition of peristaltic  movement and thus bowel motility 
x Stimulates orgasm and ejaculation 
Parasympathetic nervous system 
x Dilatation of  blood vessels of the gastrointestinal tract. 
x Bronchoconstricrion  
x Decrease heart rate and blood pressure 
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x During accommodation, constriction of the pupil and  also 
contraction of the ciliary muscle to the lens, helping in closer vision. 
x Stimulates  salivation, and  
x Accelerates  peristalsis, so,  mediates digestion of food, GIT motility 
and indirectly, the absorption of nutrients. 
x Genital erection , through the pelvic splanchnic nerves S2–4. 
 Parkinson’s diseae 
Clinically, Parkinson's disease may be defined8 as, 
x the presence of two out of the three cardinal features of 
bradykinesia, rigidity, and tremor; postural instability tends to occur 
later;  
x a good clinical response to levodopa; and 
x no 'atypical' features suggestive of another Parkinsonian syndrome. 
 Pathologically there is extensive loss of pigmented dopaminergic 
substantia nigra neurones and the presence of Lewy bodies8,37,38,39. 
Epidemiology8 
 Numerous studies have yielded crude prevalence rates of 10-400 
cases per 1,00,000 people (Zhang and Roman 1993)12. These estimates are 
difficult to compare due to different ascertainment methods. In Europe and 
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North America the prevalence has been estimated to be between 100 and 
250 per 100 000. In Europe, prevalence rates are similar in all numberries 
and there is no major difference between men and women although some 
studies have suggested that Parkinson's disease is slightly more common 
among men.  
 The usual age of onset is after 50 years with the frequency rising 
steeply with age. Onset before 40 years 'Young  onset Parkinson's disease' 
is unusual and before 20 is exceptional 'Juvenile Parkinson's disease’. 
Advancing age remains the most powerful predictor of developing 
Parkinson's disease; the lifetime risk of developing Parkinson's disease is 2 
per cent for men and 1.3 per cent for women (Elbaz et al, 2002)11. 
 Epidemiological studies have detected a variety of risk factors. The 
significance of these findings is unclear but a common thread is that 
Parkinson's disease might be due to exposure to an unidentified 
environmental toxin. Head trauma, inflammation, Caucasian ancestry, 
Nocardia infection are possible risk factors in case control studies. 
Protective factors have also been identified: smoking reduces the risk of 
Parkinson's disease by 60 per cent and coffee drinking by 30 per cent 
(Hernan ef al. 2002)10; alcohol and use of non-steroidal antiinflammatory 
drugs may also be protective. 
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Pathology of Parkinson’s disease9,25,26,27,28 
 The basic neuropathological feature8 is loss of pigmented 
dopaminergic neurones, astrocytic gliosis, dystrophic neurites, and the 
formation of Lewy bodies in the substantia nigra pars compacta37,38,39. 
However, other brain regions are also affected including other brainstem 
nuclei and the cerebral cortex. The pathological hallmark of Parkinson's 
disease is the Lewy body25, an eosinophilic intracellular inclusion8. 
Typically there is a central core within a less intensely staining body 
surrounded by a pale, halo37,38,39.  
Clinical features 
  Parkinson's disease is often regarded as an easy 'end of the 
bed' diagnosis but is highly variable in presentation and frequently 
misdiagnosed (Hughes et al. 1993b)9. Bradykinesia causes a poverty of 
movement leading to an abnormal stiffness and impassive appearance. The 
posture becomes one of flexion of the neck, spine elbows, wrists, hips and 
knees. The patient stands and walks on a narrow base. Facial expression is 
reduced with the mouth slightly open, the voice is quiet and monotonous 
and later there is a greasy skin. Some patients present with minimal and 
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easily overlooked physical signs such as slightly reduced arm swing on 
one side while walking with barely noticeable wrist rigidity brought out by 
synkinesis of the contralateral arm; others present at a surprisingly late 
stage with gross Parkinsonism and considerable disability. The most 
characteristic presentation is with tremor, bradykinesia and rigidity of an 
upper limb.  
The most reliable diagnostic principle is the presence of two out of the 
three cardinal features of: 
x Tremor 
x Bradykinesia and 
x Rigidity 
 To this could be added the presence of a good response to levodopa 
therapy which is observed In all but a handful of patients (Hughes et al 
1993b)13. 
 The Parkinsonian tremor is noticeable at rest and is less prominent 
or absent with action or posture. The frequency is slow, 4-7 Hz, and may 
involve only the thumb or one finger at first. In some patients the typical 
'pillrolling' appearance is seen but this is not invariable. The tremor is 
increased by movement of the contralateral limbs or walking. Eventually 
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the tremor spreads to the contralateral limbs but often remains more 
noticeable on the initially affected side.  
 Parkinsonian rigidity8 may be a smooth resistance to passive 
movement, ‘lead pipe' or 'plastic' rigidity, or may have a ratchet like-
cogwheel effect due to additional postural tremor. Parkinsonian rigidity is 
more obvious in the extremities and only later becomes prominent in the 
axial musculature. It is detectable with slow passive limb movement unlike 
spasticity which is related to rapid movement. It can be brought out by 
contralateral limb movement, the Froment sign8, and a useful point ill the 
outpatient clinic is that the rigidity is often more noticeable at the wrist. 
 Bradykinesia8 refers to the slowness of movement and is closely 
related to akinesia or absence of movement. There are many manifestations 
of bradykinesia including reduced facial expression, drooling of saliva, 
reduced blinking, reduced arm swing while walking, difficulty turning in 
bed or rising from a chair, slowness of gait and small shuffling steps. 
Repetitive movements show slowing and reduced amplitude; finger 
movements are particularly affected and become clumsy and laboured. 
Handwriting becomes small and spidery at an early stage, micographia. 
This may be a presenting symptom. 
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 Postural instability8 is often cited as a fourth core feature of 
Parkinson's disease but it is not often an early symptom. When walking 
there is a liability to topple forward with faster steps and difficulty 
stopping, festination. 
Autonomic Dysfunction in Parkinson’s Disease1,2,17,19 
Autonomic dysfunction in PD patients is being recognized since the 
original description by James Parkinson in 1817. Although severe ANS 
dysfunction is 
mostly seen with advanced PD, it is present in PD patients even in the 
early stages of the disease21. The symptoms of ANS dysfunction, mainly 
orthostatic hypotension and excessive sweating greatly compromise the  
quality of life  of patients.  
The pathologic process is seen in both the sympathetic and the 
parasympathetic systems as proven by the postmortem studies37,38,39.               
The  peripheral ganglia of  the sympathetic,  parasympathetic systems and  
the hypothalamus are also involved. Isotope imaging techniques have 
shown involvement of the peripheral portions of ANS and loss of 
sympathetic innervation of the heart.(Goldstein et al. 2000)14. Studies on 
PD patients  have shown   that cardiovascular autonomic dysfunction occur 
in these patients which can be assessed by cardiovascular reflex tests3,18. 
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Abnormalities noted are suppressed HR responses to breathing, the 
Valsalva manoeuvre and tilting, reflecting  the parasympathetic 
dysfunction of cardiovascular control  (Haapaniemi et al. 2000a)15, and  
pronounced BP fall in response to standing, indicating of  sympathetic 
dysfunction (Turkka et al. 1997)16. 
The pathology of PD not only involves  dopaminergic centers but also in 
the autonomic nervous system25,26,27. Rajput and Rozdilsky5 has noted that 
Lewy bodies and cell loss  occurring within the sympathetic ganglia of PD 
patients. Antibodies to sympathetic neurons also have been detected in PD 
patients.       The neurodegeneration of  PD and Lewy bodies is also seen in 
other autonomic regulatory regions, like hypothalamus28, sympathetic 
system (intermediolateral nucleus of the thoracic cord and sympathetic 
ganglia), and parasysmpathetic system (dorsal, vagal, and sacral 
parasympathetic nuclei. Lewy bodies were also seen in the adrenal medulla 
and in the neural plexi innervating the gut, heart25,26,27. This work provides 
convincing neuropathologic evidence that both the central and peripheral 
autonomic nervous systems can be affected in PD37,38,39. Autonomic 
symptoms are not disabling in early Stages of disease29.    In  early Stages 
Gastrointestinal tract autonomic symptoms are more common than 
genitourinary symptoms29. Cardiovascular symptoms are more common in 
Stages III TO V.  In Stage I,II urinary symptoms are mild, sexual 
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dysfunction sweating disturbance are present29. In Stage III severe urinary 
symptoms and orthostatic hypotension are troublesome. In Stage IV AND 
V worsening orthostatic hypertension, sialorrhoa develops and urinary 
incontinence make them disabled. 
Autonomic Function Tests 
 Autonomic function testing is gaining an important role in electro 
neurophysiology. A number of tests are used for evaluating the autonomic 
functions. The important tests are summarized. 
Tests for cardiovascular autonomic system regulation 
Sympathetic stimulation increases the heart rate and ionotropic action on 
heart, vasodilation of coronary vessels, and constriction of  resistance 
vessels30.31. The parasympathetic stimulation has the opposite effect 
although with  minimal effect on peripheral vessels. Afferent impulses 
originate in cardio-machanoreceptors, pulmonary stretch receptors, and 
arterial baroreceptors which are located in aortic arch , carotid sinus, and 
thoracic arteries. Regulation of cardiovascular autonomic functions occurs 
by a negative feedback mechanism30,31. 
Important tests used for evaluation of autonomic functions 
A. Tests of cardiovascular autonomic  system regulation  
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      Cardiovascular response on standing and Heart rate 
variability(HRV) 30:15 R-R ratio32,33 
 Head up tilt-table testing 
 HRV with respiration (sinus arrhythmia; R-R-interval analysis)  
 Valsalva maneuver and valsalva ratio  
B. Tests of thermoregulatory function 
 Sympathetic skin response(SSR),  
Quantitative sudomotor axon reflex test(QSART) 
C. Miscellaneous tests 
Exocrine  and regulation of pupil tests 
Gastrointestinal  autonomic regulation tests 
Genitourinary autonomic regulation tests 
Heart rate and Blood Pressure Recording42 
 Beat-to-beat heart rate analysis is useful, because of the heart rate 
reflexes occuring within seconds of a stimulus32. Heart rate can be 
documented on an electrocardiogram or on electromyographic equipment. 
For recording ECG signals on EMG equipment, the low filter should be set 
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at 1-5 Hz and high filter at 500 Hz; an epoch of l-2min is recorded. The 
active recording electrode is placed over the apex in midclavicular line and 
reference on lower third of sternum. Heart rate has inverse correlation with 
RR interval and can be easily calculated by the formula 
            Sweep speed (mm/s) 
Heart rate (R-R/min) =     ------------------------------------  x 60 
        R-R interval in mm 
For this test patient should be in sinus rhythm. Patients having  
premature beat and succeeding pause should not be included in the 
analysis. 
 Blood pressure(BP) is recorded from standard blood pressure 
equipment with the level of measurement being maintained at heart level.  
Cardiovascular Responses to Standing and 30:15 R-R Ratio4,6,32,33 
 Blood pressure changes on standing are studied to assess the 
integrity of the sympathetic system and heart rate changes of 
parasympathetic cholinergic (cardiovagal) functions. Normally, on 
standing, exercise reflex and mechanical effects on venous capacitance and 
arterial resistance vessels become operative in addition to gravitational 
changes {Ewing et al., 1976)7. Squeezing of capacitance. vessels by 
postural muscle results in displacement of blood toward heart, which 
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increases venous return, cardiac output, and blood pressure.         These 
changes stimulate baroreceptors, which ensure pronounced neurally 
mediated reflex and reduce sympathetic outflow, release vasoconstrictor 
tone, decrease total peripheral resistance up to 40%, and drop of BP up to 
20mmHg. These changes last for 6-8 s. Heart rate increases immediately 
upon standing and continues to rise for next several seconds, whereupon it 
slows to a maximum extent by 20 s (Ewing et al., 1976)7.  
Technique and normal values4,43,44  
BP and Heart rate are  measured after  a rest of 20 minutes initially. BP 
and heart rate are measured at baseline and then serially for 1-3 min after 
standing. ECG allows determination of 30:15 R-R ratio, i.e. the longest R-
R interval (slowest heart rate) occurring about 30 beats after standing 
divided by the shortest RR interval (fastest heart rate), which occurs about 
15 beats after standing (Ewing et al., 1976)7. 
 The diagnosis of orthostatic hypotension is based on a fall of at least 
20mmHg systolic or 10 mm of diastolic BP on assuming erect posture  but 
some authorities allow more than 30 mm systolic and 20 mm diastolic BP. 
The 30:15 R-R ratio is normally greater than 1.04 and abnormal if less than 
1.0 (Ewing et al., 1976)7. The age-related normal values of R-R ratio are 
30-49 years: 1.09; 50-65 years: 1.03.  
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Heart Rate Variation with Respiration (Sinus Arrhythmia, R-R 
Interval Analysis)33,41,42 
The study of heart rate variation with respiration is indicated for 
testing the integrity of parasympathetic cholinergic  functions33. The  
variation of heart rate with respiration is known as sinus arrhythmia40,41. 
Inspiration increases and expiration decreases the heart rate. Sinus  
arrhythmia is abolished by parasympathetic block by atropine but not 
affected by sympathetic blockade by betablockers. Pulmonary stretch 
receptors, cardiac mechanoreceptors, and possibly baroreceptors contribute 
to sinus arrhythmia33,35. It decreases with age, increases at slower 
respiratory rate reaching maximum around 5-6 respiration/min40,41.  
 Method: A simple protocol for studying sinus arrhythmia is putting 
the patient supine with  head  elevated to 30° and breathing deeply at a rate 
of 6/min, allowing 5 s each for inspiration and expiration. The maximum 
and minimum heart rate with each respiratory cycle and mean variation are 
determined. Heart rate variability(HRV) ratio is determined as the sum of 
six longest R-R intervals, divided by the sum of six shortest R-R 
intervals33,35. Normal values  for single deep breath E-I ratio at different 
age  are 41-50 years > 1.12,  51-60 years >1.09, 61-70 years >1.07.  
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 The advantage of studying sinus arrhythmia is that it is sensitive and 
can be easily carried out on most EMG equipments33,35.  
Valsalva Maneuver and Valsalva Ratio43,44  
 Valsalva maneuver helps in assessing the parasympathetic 
cholinergic functions. Valsalva maneuver has four phases. 
Phase I: 
 Phase I occurs at the onset of strain. There is transient increase in BP 
lasting for a few seconds, because  of increased intrathoracic pressure and 
mechanical squeeze of the great vessels. The heart rate, does not change in 
this phase. 
Phase II: 
 Phase II occurs during straining. In the early part, the venous return 
decreases resulting in reduction of stroke volume, cardiac output, and thus 
BP, which lasts for 4 s. In later part of phase II, BP returns toward 
baseline. This recovery occurs due to increased sympathetic 
vasoconstriction. Throughout phase II, the heart rate increases steadily, 
which is due to vagal withdrawal in the early and increased sympathetic 
activity in later part of stage II.  
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Phase III:  
 Phase III occurs following release of strain which results in transient 
decrease of BP lasting for a few seconds which is due to mechanical 
displacement of blood to pulmonary circulation, which was under 
increased intrathoracic pressure.  
Phase IV:  
 Phase IV occurs with stopping of strain. The BP slowly increases 
and HR decreases. As the BP rises to above and the HR falls below 
baseline level, it is called overshoot phenomenon. It occurs following 15-
20s after release of strain and may last for 1 min or longer. The overshoot 
phenomenon is due to increase in venous return, stroke volume, and 
cardiac output. Valsalva ratio is the ratio of maximum heart rate in phase II 
to minimal heart rate in phase IV and can be calculated as the longest R-R 
interval during phase IV to the shortest R-R interval of phase II.  
Method :  
 The patient lies supine with head elevated to 30°. The patient strains 
for 15 s against by blowing 40 mmHg through a mouthpiece  to a 
sphygmomanometer. Following stopping of the valsalva strain, the patient 
relaxes and breathes  normally. The ECG is monitored during the strain 
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and 30-45s following its release. The maximum heart rate of phase II 
actually occurs about 1 s following cessation of strain, which is generally 
taken as the maximum heart rate. The minimum heart rate occurs about 15-
20s after releasing the strain. The ratio of maximum to minimum heart rate 
is calculated by repeating the procedure 3 times.  
Miscellaneous Tests 
Blood Pressure Response to Isovolumetric exercise :  
Sustained muscular  contraction causes increased BP and heart rate as a 
result of exercise reflex, which reduces parasympathetic and increases 
sympathetic activity. Sympathetic adrenergic function is responsible for 
blood pressure changes and the parasympathetic cholinergic function is 
responsible for HR changes. In this test, the patient maintains a grip of 
30% of maximum  voluntary activity for 3-5 min. Normally, the diastolic 
BP will rise more than 15 mmHg. This test is relatively independent of age 
(Ewing et al., 1976)7. 
Blood Pressure To Mental Arithmetic43 44 
 Blood Pressure Response to Mental Stress such as arithmetic, 
sudden noise or emotional stress can result in increase in BP and heart rate 
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due to excessive sympathetic outflow. It is a useful test of sympathetic 
efferent function.  
Cold Pressor Test43,44 
 The patient submerges one upper limb in ice cold water for 60s, 
which results in rise of systolic BP by 15-20 mmHg and diastolic by 10 
mmHg. The afferent limb of the test is somatic and efferent sympathetic.  
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MATERIALS AND METHODS 
The study was conducted in Institute of  Neurology Madras Medical 
College Chennai during 2011 to 2013. The study had been approved by 
Ethical Committee of Medical Faculty Madras Medical College Chennai. 
Informed and written consent  were obtained in patient’s own language 
before their inclusion in the study. 141 patients fulfilling the criteria of 
Parkinson’s disease brain bank society8,37 were included in the study. They 
constitute both the outpatients  and inpatients of our hospital. The Study 
design is cross sectional study. 
Inclusion Criteria : 
All the patients fulfilling the criteria of Parkinson’s disease society 
brain bank were included in the study. 
Exclusion Criteria : 
All the  patients with other central or peripheral nervous system disease, 
Parkinson plus syndromes, systemic diseases and drugs that are known to 
cause ANS dysfunction were excluded from the study.  
The  patients were diagnosed based on the  following Parkinson’s disease 
society brain bank criteria8,37. 
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Parkinson's disease society brain bank criteria8,37 
1. Criteria required to 
establish the presence of 
Parkinsonism 
Bradykinesia 
Plus one of the following: 
 Rigidity 
 Resting tremor 
 Postural instability 
2.  Exclusion criteria for 
 Parkinson's disease 
Repeated stroke or stepwise progression 
Repeated head injury 
Encephalitis 
Oculogyric crises 
Recent neuroleptic treatment 
Relevant toxic exposute 
> 1 affected relative 
Sustained remission of symptoms 
Unilateral signs aftet 3 years 
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Supranuclear gaze palsy 
Cerebellar signs 
Severe, early autonomic failure 
Severe, early dementia 
Pyramidal signs 
Mass lesion or hydrocephalus on CT scan 
No response to levodopa 
3.  Positive criteria for 
 Parkinson's disease 
 (3 or more required) 
Unilateral onset 
Rest tremor 
Progressive disorder 
Persistent asymmetry 
Excellent (70-100%) response to levodopa 
Severe levodopa induced dyskinesia  
Response to levodopa lasting >5 years 
Clinical course over > 10 years 
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All the patients were clinically examined with special attention to history, 
clinical features and symptoms and signs of  Autonomic dysfunction. The 
patients were graded using the  Hoehn and Yahr staging system. 
Hoehn And Yahr Staging1 
Stage I : ҏ Only unilateral involvement, usually with minimal or no 
functional disability. 
 
Stage II : ҏBilateral disease or midline involvement  without impairment of 
balance. 
Stage III : Mild to moderate bilateral disease with impaired postural 
reflexes; physically independent. 
Stage IV :ҏ Severe disabling disease; still able to walk or stand unassisted. 
Stage V : Wheel chair bound or confinement to bed unless aided. 
All the patients were questioned about autonomic symptoms under various 
categories gastrointestinal, urinary, cardiovascular, thermoregulatory and 
sexual dysfunction and tabulated based on their presence. A number of 
drugs influence the results of autonomic testing such as anticholinergics 
adrenergic antagonists (E-blocker), sympathomimetic, 
parasympathomimetic, and drugs. affecting blood volume (diuretics and 
fludrocortisone). These drugs were discontinued before autonomic testing 
in consultation with the primary physician. The patient abstained from 
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alcohol, tea, and coffee for at least 3 hour and preferably 12 hour.
 Patient were examined in  rested and relaxed condition. All patients 
were subjected to complete general and neurological examination, 
Compressive dressings such as elastic stocking were removed before the 
test. Patients  with heart failure, obstructive lung disease, atrial fibrillation, 
and sicca syndrome were excluded. The following cardiovascular 
autonomic function tests were done for all the patients after excluding 
other causes.  
Autonomic Function Tests 
1.Blood Pressure   In Supine And  Standing After 3 Minutes 
Abnormal: Postural fall of SBP > 20 mm of Hg AND DBP >10 mm of Hg 
2. Blood Pressure Response To Sustained Handgrip 
 Abnormal:  DBP <10 mm of  Hg   Normal: DBP >15 mm of  Hg 
3. BP Variation To Mental Arithmetic 
Abnormal:  DBP <10 mm of  Hg   Normal: DBP >15 mm of  Hg 
4. BP Variation To Cold Pressor test  
Abnormal:  DBP <5 mm of  Hg   Normal: DBP >10 mm of  Hg 
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5. Heart Rate Variability Ratio To standing 
Abnormal: < 1.04 
6. Heart Rate Variability Ratio To Valsalva 
Abnormal: <1.2 
7. Heart Rate Variability Ratio To Deep Breathing 
Abnormal : <1.0 
The following results were considered as abnormal in cardiovascular 
autonomic function tests. 
Valsalva ratio of less than 1.2 is regarded as abnormal, 1.2-1.45 as 
borderline and greater than 1.45 as normal (Ewing, 1976). Valsalva ratio 
decreases with age. The age specific norms are more precise:  41-60 years 
> 1.45,  61-70 years >1.35 (Low, 2004)43,44  
Normal values  for single deep breath E-I ratio at different age  are 41-50 
years > 1.12,  51-60 years >1.09, 61-70 years >1.07.  
Patients with ANS system were graded in severity depending on the 
number of systems involved. The systems include gastrointestinal, urinary, 
cardiovascular, thermoregulatory and sexual dysfunction, The results were 
graded as follows. 
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Mild : Involvement of One to two systems 
Moderate: Involvement of Three systems 
Severe: Involvement of More than three systems 
The results were analysed through SPSS  version 20 ( Statistical Package 
for the Social Sciences or Superior Performing Statistical Software)  
statistical analysis by  Pearson Chi-square  test  and p values obtained. 
  
  
 
 
 
 
 
 
 
 
 
RESULTS 
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OBSERVATION AND RESULTS 
A total of 141 patients of Parkinson’s disease, both inpatients and 
outpatients of Rajiv Gandhi Govt. General Hospital, Institute Of 
Neurology Madras Medical College between 2011 to 2013, were analysed  
and the results of analysis are as follows 
1. Sex Distribution: 
Among 141 patients enrolled 87  were males and 54 were females 
MALES  87 
FEMALES  54 
TOTAL  141 
 
Figure 1:SEXWISE DISTRIBUTION OF PATIENTS 
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2. Age Distribution: 
 The mean age of male patients was 54 years, and female was 52 
years. The highest age among male patients was 70 and the lowest age  
was 40. The patients were grouped as follows 
Age (Years) Patients  Percentage(%) 
41-50 57 40.4% 
51-60 45 31.9% 
61-70 39 27.7% 
Total  141 100% 
 
Figure 2: AGE GROUP WISE DISTRIBUTION 
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3. Hoehn and Yahr Staging of patients: 
Patients were classified based on Hoehn and Yahr staging Stage I  to V. 
Stage IV AND V were grouped into onem as the  number of patients was 
less . 
53  patients viz 32 males and 21 females belonged to Stage I of 
Parkinson’s Disease; 44  patients viz 25 males and 19 females belonged to 
Stage II of Parkinson’s Disease; 28  patients viz 18 males and 10 females 
belonged to Stage III of Parkinson’s Disease; 16  patients viz 12 males and 
4 females belonged to Stage IV of Parkinson’s Disease. 
 
Staging 
No of 
Male 
Patients 
No of Female 
Patients 
Total 
Stage I 32 21 53 
Stage II 25 19 44 
Stage III 18 10 28 
Stage IV & V 12 4 16 
Total 87 54 141 
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Figure 3: STAGE WISE SEX DISTRIBUTION OF PATIENTS 
 
4. Prevalence  of patients with ANS dysfunction 
Among 141 patients, 118(83.7%) had autonomic dysfunction. 
Figure 4: Prevalence  of patients with ANS dysfunction 
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5. Sex distribution of PD Patients Having ANS Dysfunction 
Among 87 males, 72 patients had ANS dysfunction and among  54 
females, 46 patients had ANS dysfunction. 
SEX Total PD 
Patients 
Patients With 
ANS 
Dysfunction 
MALES 87 72(82.75%) 
FEMALES 54 46(85.2%)   
TOTAL 141 118(83.7%) 
                       
Figure 5: SEX DISTRIBUTION OF ANS DYSFUNCTION 
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6.  Stagewise distribution of PD Patients With ANS Dysfunction 
Stage wise 39 of 53 patients(73.6%)  belonging to Stage I; 37 of 44 
(84.1%) belonging to Stage II; 26 of 28 (84.1%) belonging to Stage III and 
all patients belonging to Stage IV and V had ANS dysfunction. 
Figure 6: Depicts increasing prevalence of ANS dysfunction as stage increases 
 
 
 
 
 
 Staging 
Total No. Of  
Patients 
Patients  
With ANS 
Dysfunction 
% Of Patients 
With ANS 
Dysfunction 
Stage I 
53 
39 73.6% 
Stage II 
44 
37 84.1% 
Stage III 
28 
26 92.9% 
Stage IV and V 
16 
16 100% 
Total  
141 
118 83.7% 
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7. Stage wise Prevalence Of Male PD Patients With ANS Dysfunction: 
Among  male patients, 22 out of 32  belonging to Stage I  of PD,  21 out of 
25  belonging to Stage II, 17 out of 18 belonging to Stage III and all 
patients of Stage IV and V(100%) had autonomic dysfunction. 
 Staging 
Total 
No. Of  
Males 
Patients  
With Ans 
Dysfunction 
% Of Males 
With Ans 
Dysfunction 
Stage I 32 22 68.75% 
Stage II 25 21 84.00% 
Stage III 18 17 94.40% 
Stage IV and V 12 12 100% 
Total  87 72 82.75% 
 
                                    Figure 7:  Stagewise Prevalence of male PD Ppatients with ANS dysfunction 
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8. Stagewise Prevalence Of  Female PD Patients With ANS 
Dysfunction  
Among  female patients, 17 out of 21 belonging to Stage I; 16 out of 19 
belonging to Stage II, 9 out of 10 belonging to Stage III and all patients of 
Stage IV(100%) had autonomic dysfunction. 
 Staging 
Total No. 
Of  
Females 
Patients  
With Ans 
Dysfunction 
% Of Females 
With Ans 
Dysfunction 
Stage I 21 17 80.9% 
Stage II 19 16 84.2% 
Stage III 10 9 90% 
Stage IV& V 4 4 100% 
Total  54 46 90.7% 
 
Figure 8: Stagewise Prevalence Of  Female PD Patients With ANS Dysfunction 
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9. Prevalence Of Systemwise distribution of ANS Dysfunction in PD 
Patients: 
Among 118 patients, 61male and 21 female had sexual dysfunction, 34 
males and 36 females had urinary dysfunction, 41 males and 22 females 
had gastrointestinal tract dysfunction, 27  males and 26 females had 
cardiovascular dysfunction, 37 males and 30 females  had 
thermoregulatory dysfunction. Patients had ANS dysfunction in multiple 
categories. 
 Categories Males Females 
Sexual 61(84.7%) 21(45.7%) 
Urinary 34(47.2%) 36(78.3%) 
GIT 41(56.9%) 22(47.8%) 
Cardiovascular 27(37.5%) 26(56.5%) 
Thermoregulatory 37(51.3%) 30(65.2%) 
 
Figure 9: PREVALENCE OF  SYSTEMWISE  ANS DYSFUNCTION IN PD PATIENTS BOTH MALES 
AND FEMALES 
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10. Age Correlation With Severity Of ANS Dysfunction 
 In 40-50 years age group, 38.6% (n-22) did not have ANS dysfunction; 
49.1% had mild ANS dysfunction ; 12.3% had moderate ANS dysfunction 
; none  had severe  ANS dysfunction. But on the contrary in 60-70 age 
group, 12.8% had moderate ANS dysfunction and 94.4%  severe ANS 
dysfunction. The results are tabulated as follows: 
    Severity Total  
    Nil Mild Moderate Severe   P VALUE 
Age in years 40-50 Number 22 28 7 0 57  
    %  of patients within 
same Age group 
38.6% 49.1% 12.3% .0% 100.0% 
<0.0001 
    %  of patients within 
same severity grading 
95.7% 71.8% 16.3% .0% 40.4% 
<0.0001 
  50-60 Number 1 11 31 2 45  
    %  of patients within 
same Age group 
2.2% 24.4% 68.9% 4.4% 100.0% 
<0.0001 
    %  of patients within 
same severity grading 
4.3% 28.2% 72.1% 5.6% 31.9% 
<0.0001 
  60-70 Number 0 0 5 34 39  
    %  of patients within 
same Age group 
.0% .0% 12.8% 87.2% 100.0% 
<0.0001 
    %  of patients within 
same severity grading 
.0% .0% 11.6% 94.4% 27.7% 
<0.0001 
Total Number 23 39 43 36 141  
  %  of patients within 
same Age group 
16.3% 27.7% 30.5% 25.5% 100.0% 
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FIG 10: Age Correlation With Severity Of ANS Dysfunction 
 
 
11. Sex Correlation With  Severity Of ANS Dysfunction 
On analysing sex distribution with severity of dysfunction,  among 
males 17.2% (n-15) did not have ANS dysfunction; 27.6% (n-24) had mild 
ANS dysfunction ; 26.4%(n-23)  had moderete ANS dysfunction ; 
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28.7%(n-25)   had severe  ANS dysfunction. In females 14.8% (n-8) did 
not have ANS dysfunction; 27.8% (n-15) had mild ANS dysfunction ; 
37.0%(n-20)  had moderete ANS dysfunction ; 20.4%(n-11)   had severe  
ANS dysfunction The results are tabulated as follows: 
    Severity Total 
    Nil Mild Moderate Severe   
Sex Male Number 15 24 23 25 87 
    %  of patients within 
same sex 
17.2% 27.6% 26.4% 28.7% 100.0% 
    %  of patients within 
same severity grading 
65.2% 61.5% 53.5% 69.4% 61.7% 
  Female Number 8 15 20 11 54 
    %  of patients within 
same sex  
14.8% 27.8% 37.0% 20.4% 100.0% 
    %  of patients within 
same severity grading 
34.8% 38.5% 46.5% 30.6% 38.3% 
Total Number 23 39 43 36 141 
  %  of patients within 
same sex 
16.3% 27.7% 30.5% 25.5% 100.0% 
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FIG 11: Sex Correlation With Severity Of ANS Dysfunction(p <0.05) 
 
 
12. Disease Duration In Years Correlation With Severity Of ANS 
Dysfunction 
The results of correlation of duration of  PD with severity of ANS 
dysfunction were tabulated as follows. 
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    Severity of ANS dysfunction Total  
   Nil Mild Moderate Severe   P VALUE  
Disease 
duration in 
years 
Upto 5 number 
14 35 7 0 56 
 
    %  of patients 
with ANS 
dysfunction 
within same 
duration group 
25.0% 62.5% 12.5% .0% 100.0% 
<0.0001 
    %  of patients 
within same 
severity grading 
60.9% 89.7% 16.3% .0% 39.7% 
<0.0001 
  5-7.5 Number 7 4 29 2 42  
    %  of patients 
ANS dysfunction 
within same 
duration group 
16.7% 9.5% 69.0% 4.8% 100.0% 
<0.0001 
    %  of patients 
within same 
severity grading 
30.4% 10.3% 67.4% 5.6% 29.8% 
<0.0001 
  7.5-10 Number 2 0 5 17 24  
    %  of patients 
with ANS 
dysfunction 
within same 
duration group 
8.3% .0% 20.8% 70.8% 100.0% 
<0.0001 
    %  of patients 
within same 
severity grading 
8.7% .0% 11.6% 47.2% 17.0% 
<0.0001 
  Above 10 Number 0 0 2 17 19  
    %  of patients 
with ANS 
dysfunction 
within same 
duration group 
.0% .0% 10.5% 89.5% 100.0% 
<0.0001 
    %  of patients 
within same 
severity grading 
.0% .0% 4.7% 47.2% 13.5% 
<0.0001 
Total Number 23 39 43 36 141  
  
 
 
%  of patients 
within same 
duration group 
 
16.3% 27.7% 30.5% 25.5% 100.0% 
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12. Disease Duration In Years Correlation With Severity Of ANS Dysfunction 
 
 
 
 
 
 
 
 
 
13. Hoehn And Yahr Stage Wise Severity Of Dysfunction  
The results of correlation of  Hoehn and Yahr stage with severity of 
ANS dysfunction were tabulated as follows. 
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   Severity Total  
    Nil Mild Moderate Severe   P value 
Staging I Number 14 33 6 0 53  
    %  of patients with ANS 
dysfunction within same 
Staging 
26.4% 62.3% 11.3% .0% 100.0% 
<0.0001 
    %  of patients within 
same severity grading 
60.9% 84.6% 14.0% .0% 37.6% 
<0.0001 
  II Number 7 6 30 1 44  
    %  of patients with ANS 
dysfunction within same 
Staging 
15.9% 13.6% 68.2% 2.3% 100.0% 
<0.0001 
    %  of patients within 
same severity grading 
30.4% 15.4% 69.8% 2.8% 31.2% 
<0.0001 
  III Number 2 0 7 19 28  
    %  of patients with ANS 
dysfunction within same 
Staging 
7.1% .0% 25.0% 67.9% 100.0% 
<0.0001 
    %  of patients within 
same severity grading 
8.7% .0% 16.3% 52.8% 19.9% 
<0.0001 
  IV & 
V 
Number 
0 0 0 16 16 
 
    %  of patients with ANS 
dysfunction within same 
Staging 
.0% .0% .0% 100.0% 100.0% 
<0.0001 
    %  of patients within 
same severity grading 
.0% .0% .0% 44.4% 11.3% 
<0.0001 
Total Number 23 39 43 36 141  
  %  of patients within 
same Staging 
16.3% 27.7% 30.5% 25.5% 100.0% 
<0.0001 
  %  of patients within 
same severity grading 
100.0% 
100.0
% 
100.0% 100.0% 100.0% 
<0.0001 
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FIG 13: Stagewise Correlation With Severity Of ANS Dysfunction depicting more severity in stage III and IV 
 
14.Correlation Of Individual Autonomic Function Tests With Staging   
14.a. Abnormal  BP On Mental Arithmetic 
 
The results of BP on Mental Arithmetic were correlated with staging 
of disease and tabulated as follows. 
    
Response of BP on Mental 
arithmetic Total 
 
    Normal Abnormal   p value 
Staging I Number 53 0 53  
    %  of patients within same Staging 100.0% .0% 100.0% <0.0001 
    % of patient  within same response 50.0% .0% 37.6% <0.0001 
  II Number 42 2 44  
    %  of patients within same Staging 95.5% 4.5% 100.0% <0.0001 
    % of patient  within same response 39.6% 5.7% 31.2% <0.0001 
  III Number 11 17 28  
    %  of patients within same Staging 39.3% 60.7% 100.0% <0.0001 
    % of patient  within same response 10.4% 48.6% 19.9% <0.0001 
  IV 
& V 
Number 
0 16 16 
 
    %  of patients within same Staging .0% 100.0% 100.0% <0.0001 
    % of patient  within same response .0% 45.7% 11.3% <0.0001 
Total Number 106 35 141  
  %  of patients within same Staging 75.2% 24.8% 100.0%  
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FIG 14a: STAGING  CORRELATION WITH ABNORMAL  BP ON MENTAL ARITHMETIC 
 
14.b. Correlation With Abnormal BP On Cold Pressor Test 
  The results of BP on Cold pressor test  were correlated with staging 
of disease and tabulated as follows. 
    Response of BP on Cold Total  
    Normal Abnormal    p value 
Staging I Number 53 0 53  
    %  of patients within same Staging 100.0% .0% 100.0% <0.0001 
    % of patient  within same response 50.0% .0% 37.6% <0.0001 
  II Number 41 3 44  
    %  of patients within same Staging 93.2% 6.8% 100.0% <0.0001 
    % of patient  within same response 38.7% 8.6% 31.2% <0.0001 
  III Number 12 16 28  
    %  of patients within same Staging 42.9% 57.1% 100.0% <0.0001 
    % of patient  within same response 11.3% 45.7% 19.9% <0.0001 
  IV 
& V 
Number 
0 16 16 
 
    %  of patients within same Staging .0% 100.0% 100.0% <0.0001 
    % of patient  within same response .0% 45.7% 11.3% <0.0001 
Total Number 106 35 141  
  %  of patients within same Staging 75.2% 24.8% 100.0%  
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Fig 14b: Stage Wise Correlation With Abnormal BP On Cold Pressor Test 
 
 
 
 
 
 
 
 
Staging
4321
C
ou
nt
60
50
40
30
20
10
0
BP on Cold
Normal
Abnormal
50 
 
Staging
4321
C
ou
nt
60
50
40
30
20
10
0
BP on Standing
Normal
Abnormal
14.c. Stage Wise Correlation With BP On Standing 
  The results of BP on standing were correlated with staging of 
disease and tabulated as follows. 
    
 Response of BP on 
Standing Total 
 
    Normal Abnormal   p value 
Staging I Number 53 0 53  
    % of patients within  same Stage 100.0% .0% 100.0% <0.0001 
    % of patient  within same response 50.0% .0% 37.6% <0.0001 
  II Number 42 2 44  
    % of patients within  same Staging 95.5% 4.5% 100.0% <0.0001 
    % of patient  within same response 39.6% 5.7% 31.2% <0.0001 
  III Number 10 18 28  
    % of patients within  same Staging 35.7% 64.3% 100.0% <0.0001 
    % of patient  within same response 9.4% 51.4% 19.9% <0.0001 
  IV & 
V 
Number 
1 15 16 
 
    % of patients within  same Staging 6.3% 93.8% 100.0% <0.0001 
    % of patient  within same response .9% 42.9% 11.3% <0.0001 
Total Number 106 35 141  
  % of patients within  same Staging 75.2% 24.8% 100.0%  
 
 
 
   
 
 
 
 
 
 
 
 
 
 
 
 
FIG 14c: Stage Wise Correlation With BP On Standing depicting abnormality worsens as stage 
increases 
51 
 
14.d. Correlation With BP On  Isovolumetric Exercise 
The results of BP on isovolumetric exercise were correlated with 
staging of disease and tabulated as follows. 
    
Response of BP on  
isovolumetric Excercise Total 
 
    Normal Abnormal   p value 
Staging I Number 53 0 53  
    % of patients within  same Staging 100.0% .0% 100.0% <0.0001 
    % of patient  within same response 47.3% .0% 37.6% <0.0001 
  II Number 42 2 44  
    % of patients within  same Staging 95.5% 4.5% 100.0% <0.0001 
    % of patient  within same response 37.5% 6.9% 31.2% <0.0001 
  III Number 14 14 28  
    % of patients within  same Staging 50.0% 50.0% 100.0% <0.0001 
    % of patient  within same response 12.5% 48.3% 19.9% <0.0001 
  IV & 
V 
Number 3 13 16  
    % of patients within  same Staging  18.8% 81.3% 100.0% <0.0001 
    % of patient  within same response 2.7% 44.8% 11.3% <0.0001 
Total Number 112 29 141  
  % of patients within  same Staging 79.4% 20.6% 100.0%  
 
Fig 14d: Stage Wise Correlation With BP On  Isovolumetric Exercise depicting more normality in 
stages I and II, more abnormality in stage III and IV 
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14.e. Correlation With HRV On Standing 
The results of heart rate variability were correlated with staging of 
disease. 53 patients(100%)  had normal HRV in stage I, whereas in stage 
IV  and   V, only 6.2% had normal HRV and 93.8%% had abnormal HRV 
on standing. The results  are  tabulated as follows. 
    
Response of HRV on 
standing Total 
 
    Normal Abnormal   P value 
Staging I Number 53 0 53  
    %  of patients within same Staging 100.0% .0% 100.0% <0.0001 
    % of patient  within same response 54.1% .0% 37.6% <0.0001 
  II Number 36 8 44  
    %  of patients within same Staging 81.8% 18.2% 100.0% <0.0001 
    % of patient  within same response 36.7% 18.6% 31.2% <0.0001 
  III Number 8 20 28  
    %  of patients within same Staging 28.6% 71.4% 100.0% <0.0001 
    % of patient  within same response 8.2% 46.5% 19.9% <0.0001 
  IV 
V 
Number 1 15 16  
    %  of patients within same Staging 6.3% 93.8% 100.0% <0.0001 
    % of patient  within same response 1.0% 34.9% 11.3% <0.0001 
Total Number 98 43 141  
  %  of patients within same Staging 69.5% 30.5% 100.0%  
 
 
 
 
 
 
 
 
 
 
Fig 14g: Stage Wise Correlation With HRV On  standing depicting more normal ratio  in stages I 
and II, more abnormal HRV  in stage III and IV 
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14.f. Correlation With  heart rate variability On Valsalva 
The results of BP on HRV on vasalva were correlated with staging of 
disease and tabulated as follows. 
    
Resonse of HRV on 
Valsalva Total 
 
    Normal Abnormal   P value 
Staging 1 Number 53 0 53  
    % of patients within  same Staging  100.0% .0% 100.0% <0.0001 
    % of patient  within same response 53.5% .0% 37.6% <0.0001 
  2 Number 39 5 44  
    % of patients within  same Staging 88.6% 11.4% 100.0% <0.0001 
    % of patient  within same response 39.4% 11.9% 31.2% <0.0001 
  3 Number 7 21 28  
    % of patients within  same Staging 25.0% 75.0% 100.0% <0.0001 
    % of patient  within same response 7.1% 50.0% 19.9% <0.0001 
  4 Number 0 16 16  
    % of patients within  same Staging .0% 100.0% 100.0% <0.0001 
    % of patient  within same response .0% 38.1% 11.3% <0.0001 
Total Number 99 42 141  
  % of patients within  same Staging 70.2% 29.8% 100.0%  
 
Fig 14f: Stage Wise Correlation With HRV On  Valsalva depicting more normal ratio  in stages I 
and II, more abnormal HRV  in stage III and IV 
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14.g.  Correlation With Heart rate variability  On Respiration 
  The results of BP on HRV on respiration were correlated with 
staging of disease and tabulated as follows. 
    
Response of HRV on 
Respiration Total 
 
    Normal Abnormal   P value 
Staging I Number 53 0 53  
    %  of patients within same Staging 100.0% .0% 100.0% <0.0001 
    % of patient  within same response 53.0% .0% 37.6% <0.0001 
  II Number 38 6 44  
    %  of patients within same Staging 86.4% 13.6% 100.0% <0.0001 
    % of patient  within same response 38.0% 14.6% 31.2% <0.0001 
  III Number 8 20 28  
    %  of patients within same Staging 28.6% 71.4% 100.0% <0.0001 
    % of patient  within same response 8.0% 48.8% 19.9% <0.0001 
  IV & V Number 1 15 16  
    %  of patients within same Staging 6.3% 93.8% 100.0% <0.0001 
    % of patient  within same response 1.0% 36.6% 11.3% <0.0001 
Total Number 100 41 141  
  %  of patients within same Staging 70.9% 29.1% 100.0%  
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Fig 14g: Stage Wise Correlation With HRV On  respiration depicting  more abnormal ratio  in 
stage III and IV. 
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DISCUSSION 
A total of 141  patients both inpatients and outpatients of Rajiv 
Gandhi Govt. General Hospital, Institute Of Neurology Madras Medical 
College between 2011 and 2013 with clinical feature  suggestive of  
Parkinson’s Disease were analysed. 
 Among 141 patients enrolled in the study 87 were males and 54 
were females with the ages ranging from 40-70 years in males and 
females,   
The  mean age of males and females were 54 years and 52 years 
respectively. 57(40.4%) of patients were in the age group of 40years to 50 
years; 45(31.9%) of patients were in the age group of  51 years to 60 years;  
39(27.7%) of patients were in the age group of 61 years to 70 years.  
On classification based on staging, 53  patients viz 32 males and 21 
females belonged to Stage I of Parkinson’s Disease; 44  patients viz 25 
males and 19 females belonged to Stage II of Parkinson’s Disease; 28  
patients viz 18 males and 10 females belonged to Stage III of Parkinson’s 
Disease; 16  patients viz 12 males and 4 females belonged to Stage IV and 
V of Parkinson’s Disease 
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Overall 118 out of 141 patients (83.7%) of patients had ANS 
dysfunction. Among 87 males, 72 patients (82.75%) had ANS dysfunction 
and among  54 females, 46 patients(85.2%)  had ANS dysfunction.  Singer 
et al   noted that 89% of  Parkinsonian patients had at least one of the 
autonomic symptoms. 80-90 % of PD patients have some ANS  symptoms 
as per Turkka  et al (1986)55.This  is consistent with our study where ANS 
symptoms were present in 83.7% of PD patients. 
Among  male patients, 22 out of  32(68.75%) belonging to Stage I; 
21 out of 25(84%)  belonging to Stage II, 17 out of 18(94.4%)  belonging 
to Stage III and all patients(100%)  of Stage IV had autonomic 
dysfunction.  Among  female patients, 17 out of  21(80.9%) belonging to 
Stage I ;16 out of 19(84.2%) belonging to Stage II, 9 out of 10(90%) 
belonging to Stage III and all patients(100%) of Stage IV had autonomic 
dysfunction. Overall  Stage wise 39 patients of 53 patients(73.6%)  
belonging to Stage I; 37 of 44 (84.1%) belonging to Stage II; 26 of 28 
(84.1%) belonging to Stage III and all patients(100%) belonging to Stage 
IV and V had ANS dysfunction. Hence as the staging of PD increases the 
prevalence of ANS dysfunction increases both in males and females. Thus  
ANS dysfunction significantly correlates with staging of  PD  in both sexes 
which is similar  with studies of Zesiewicz TA et al51 and Pospíšil P et al52 
in their series. 
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Among 118 patients, 61male(84.7%) and 21(45.7%)  female had 
sexual dysfunction, 34 males(47.2%)  and 36 females(78.3%)  had urinary 
dysfunction, 41 males(56.9%)  and 22 females(47.8%)  had gastrointestinal 
tract dysfunction, 27  males(37.5%)  and 26 females(56.5%)  had 
cardiovascular dysfunction,37 males(51.3%)  and 30 females(65.2%)   had 
thermoregulatory dysfunction. Patients had ANS dysfunction in multiple 
categories and the percentages observed were within same gender. Among 
males sexual dysfunction was the most common ANS dysfunction 
followed  by  gastrointestinal tract dysfunction, thermoregulatory 
dysfunction, urinary dysfunction,  and  cardiovascular dysfunction in that 
order. Among females urinary dysfunction  was the most common 
followed by thermoregulatory dysfunction and cardiovascular dysfunction. 
Wüllner U et al54 in his analysis of Autonomic dysfunction in 3414 
Parkinson's disease patients have reported Orthostatic hypotension in 10% 
of women and 11% of men, urinary incontinence in 22% of women and 
21% of men, sexual dysfunction in 8% of women and 30% of men (50% of 
whom reported erectile dysfunction). According to Singer C et al53, who 
evaluated autonomic function in forty-eight men with Parkinson's disease 
(PD), found a higher prevalence of the following symptoms of autonomic 
dysfunction in the PD patients: erectile dysfunction (60.4 vs. 37.5%), 
sensation of incomplete bladder emptying (41.6 vs. 15.6%), urgency (45.8 
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vs. 3.125%), constipation (43.9 vs. 6.25%), dysphagia (22.9 vs. 6.25%) 
and orthostatic dizziness (21.95 vs. 0%). Sexual  dysfunction  ranks first 
similar to our study. 
On correlating the age with ANS dysfunction, in 40- 50 
group,22(38.6%) did not have ANS dysfunction 28(49.1%) had mild ANS 
dysfunction  7(12.3%) had moderate ANS dysfunction and none had 
severe dysfunction. In 50-60 age group, 1 (2.2%) did not have ANS 
dysfunction, 11(24.4%) had mild ANS dysfunction,  31(68.9%) had 
moderate ANS dysfunction and 2(4.4%) had severe dysfunction. In 60-70 
age group, 5(12.8%) had moderate ANS dysfunction and 34(87.2%) had 
severe dysfunction.  In intial years of the disease, patients  did not have 
ANS dysfunction or only mild to moderate ANS dysfunction only. But  as 
the age advances the severity of dysfunction increases, which is 
statistically significant (p value<0.0001).  There   is no significant 
correlation between males and females reagarding the severity of ANS 
dysfunction. 
 On analysing the disease duration with ANS dysfunction, in upto 5 
years group,14(25%) did not have ANS dysfunction, 35(62.5%) had mild 
ANS dysfunction  7(12.5%) had moderate ANS dysfunction and none had 
severe dysfunction. In 5-7.5 years group, 7 (16.7%) did not have ANS 
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dysfunction, 4(9.5%) had mild ANS dysfunction,  29(69%) had moderate 
ANS dysfunction and 2(4.8%) had severe dysfunction. In 7.5-10 years 
group, 2(8.3%) did not have ANS dysfunction 5(20.8%) had moderate 
ANS dysfunction and 17(70.8%) had severe dysfunction.  In more than 10 
years group,2(10.5%) had moderate ANS dysfunction and 17(89.5%) had 
severe dysfunction. As the disease duration advances the severity of 
dysfunction increases,with patients in older age group having disease 
duration more than 10 years have moderate to severe ANS dysfunction and 
which is statistically significant (p value<0.0001).   
  On analysing the staging with severity of  ANS dysfunction, 
in Stage I, 14(26.4%)  patients did not have ANS dysfunction, 33(62.3%) 
had mild ANS dysfunction  6(11.3%) had moderate ANS dysfunction and 
none had severe dysfunction. In Stage II, 7 (15.9%) did not have ANS 
dysfunction, 6(13.6%) had mild ANS dysfunction,  30(68.2%) had 
moderate ANS dysfunction and 1(2.3%) had severe dysfunction. In Stage 
III, 2(7.1%) did not have ANS dysfunction 7(25%) had moderate ANS 
dysfunction and 19(67.9%) had severe dysfunction.  In Stage  IV and V,  
all 16 patients (100%)  had severe dysfunction. As the staging advances 
the severity of dysfunction increases.  All patients in Stage IV and V 
patients had severe ANS dysfunction in all patients  which is statistically 
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significant (p value<0.0001).  Pospíšil P and Koneþný L  et al52 in their 
study has concluded that autonomic nervous system dysfunction is more 
severe in advanced stages of  Hoehn and Yahr (stages 2 and 3)  than early 
stages (stage 1) . Hoehn & Yahr (H&Y) stage, disease duration,  and age at 
onset all showed significant correlations with Autonomic dysfunction 
(Zesiewicz TA et al)51. 
On analysing various sympathetic tests, BP on cold pressor test, BP on 
isovolumetric exercise, BP on standing, BP on valsalva manouvere, as the 
stage worsens the abnormality of  BP measurements increases and thus 
they all are significantly correlated with the staging and thus severity. 
Orthostatic  hypotension makes the patients in terminal stages disabled.  
Similarly on anlaysing parasympathetic cardiovascular function tests, 
Heart rate variability ratio(HRV) on standing, HRV on valsalva, HRV on 
respiration,were abnormal as the staging and disease  worsens.  Meco et 
al22 in his study of Cardiovascular reflexes and autonomic dysfunction in 
Parkinson's disease analysed in 20 cases  heart rate variation during normal 
respiration,standing and during the Valsalva manoeuvre and blood 
pressure variation after standing and concluded that significant changes in 
the different heart rate variation indices were found in the Parkinsonian 
patients that correlates with both the duration and severity of the 
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extrapyramidal symptomatology. These results were in consistent with our 
study. Ludin SM, and  Steiger UH et al45 analysed cardiovascular reflexes 
in 22 patients and have concluded  the heart rate variation evoked by deep 
breathing as well as the blood pressure response and the heart rate response 
to sustained isometric exercise were significantly diminished in the 
patients with idiopathic Parkinson's disease. S.J. Piha, , J.O. Rinne, U.K. 
Rinne et al 47,48,49  in their study of Autonomic dysfunction in recent onset 
and advanced Parkinsons’s disease, have concluded that in Parkinson's 
disease a parasympathetic damage occurs which worsens during the course 
of the disease,  and also the orthostatic fall in blood pressure, indicating a 
sympathetic dysfunction20. The dysfunction of cardiovascular autonomic 
control is thought to correlate with the severity of the disease . (van Dijk et 
al. 1993)23,24,50,. 
   Hence  prevalence of ANS dysfunction is high in Parkinson disease 
patients.  It correlates well with Age, Duration, Hoehn and Yahr staging. 
Cardiovascular autonomic function tests also correlate with staging and 
thus severity of disease. Advancement in management of autonomic 
symptoms stresses the need for identification of ANS symptoms early so 
that early treatment gives them good quality of life.  
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CONCLUSIONS 
Autonomic nervous system dysfunction in Parkinson’s disease is  a 
common  problem and it has to be identified early to initiate proper 
treatment. We conclude the following from our study. 
1. The prevalence of ANS dysfunction is significantly high in PD 
patients of  83.7% . The prevalence is 82.75% in males and 85.2% in 
females.   
2.  The prevalence of  ANS dysfunction  in Males increases as the 
Hoehn and Yahr stage increases as evidenced by 68.7% of males in 
stage  I  and  100%  of  males  in  stage  IV  and  V   have  ANS  
dysfunction. 
3.   The prevalence of  ANS dysfunction  in Females increases as the 
Hoehn and Yahr stage increases as evidenced by 80.9% of females 
in stage I and 100% of  Females in stage IV and V  have ANS 
dysfunction. 
4.  Sexual dysfunction(84.7%)  is the most common ANS dysfunction 
in males followed  by gastrointestinal(56.9%), and thermoregulatory 
(51.3%) autonomic disturbances.  
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5. Urinary  disturbances(78.3%),  is the most common ANS 
dysfunction in females followed by thermoregulatory(65.2%),, and 
cardiovascular  disturbances(56.5%). 
6.   There is a significant correlation between the age and ANS 
dysfunction.  The severity of dysfunction worsens as the age 
advances, which is statistically significant (p value<0.0001) 
7.  There is no significant correlation between the sex and severity of  
ANS dysfunction. 
8.  As the disease duration advances the severity of dysfunction 
increases which is statistically significant (p value<0.0001). Patient 
with disease duration less than 5 years had no or only mild ANS 
dysfunction, whereas with patients with disease duration more than 
10 years had predominantly moderate to severe ANS dysfunction in 
all patients.  
9. There exists a significant correlation between Hoehn and Yahr 
staging and severity of ANS dysfunction. Patient in stage I had no 
ANS dysfunction(26.4%)  or only mild dysfunction(62.3%)  
whereas  patients in stage IV and V   have severe ANS dysfunction 
(100%). 
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10. The prevalence of abnormality in Sympathetic  cardiovascular 
autonomic function tests viz BP on cold pressor test, BP on 
isovolumetric exercise, BP on standing, BP on valsalva manouvere, 
increases  as the stage worsens significantly.  
11.  The  prevalence of  abnormality in Parasympathetic cardiovascular 
autonomic function tests viz Heart rate variability ratio(HRV) on 
standing, HRV on valsalva, HRV on respiration, also increases as 
the stage increases. 
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Abbreviations 
 
 
 
ANS           Autonomic nervous system 
HRV                     Heart rate variability ratio 
BP                        Blood pressure 
CNS                     Central nervous system 
ECG                     Electrocardiogram 
EMG                    Electromyogram 
HR                        Heart rate 
MSA                   Multiple system atrophy 
PD             Parkinson’s disease 
RSA             Respiratory sinus arrhythmia 
SSR            Sympathetic skin response 
QSART               Quantitative sudomotor axon reflex test 
SBP           Systolic blood pressure 
DBP                   Diastolic blood pressure 
n         number of patients 
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INTRODUCTION Parkinson’s disease (PD)1 is a chronic neurodegenerative progressive
neurological disease with clinical features viz rigidity, bradykinesia, rest tremor and postural
instability. Assymetry is a prominent feature of this disease.PD ranks second among the common
neurodegenerative disease next only to Alzheimer’s dementia. The pathological characteristic of PD is
intraneuronal alpha synuclein positive Lewy bodies and loss of neuronal cell. Apart from classical
motor symptoms PD patients also develop non motor symptoms. Non motor symptoms cause a
major disability in PD and the prominently contribute to decreasing quality of life especially in
advanced stages of disease. The major...
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PROFORMA 
  
 PROFORMA 
STUDY OF AUTONOMIC NERVOUS   SYSTEM  DYSFUNCTION 
IN PARKINSONISM 
 
Name  :       MIN NO : 
 
Age    :       S.NO     : 
 
Sex    :       DATE  : 
 
Diagnosis  : 
 
 
 
Duration of disease : 
 
 
Symptomatology and duration: 
 
Rigidity   : 
Tremor   : 
Postural instability : 
Bradykinesia  : 
Other features  
1.     : 
2.     : 
3.     : 
 Symmetrical /assymetrical 
 
 
 
Treatment history : 
 Drugs ,dose,duration    : 
 
 
Clinical improvement   :           static /improved/worsening 
 
General examination: 
 
 
Systemic examination: 
 
 
 
 
 
 
 
 
Others: 
 
 
 
 
DM /SHT/OTHER SYSTEMIC DISEASES 
 SMOKER : YES/NO                                                       ALCOHOLIC: 
YES/NO 
 
BLOOD SUGAR 
UREA 
CREATININE 
 
LIPID PROFILE 
 
 
 
CT BRAIN/ MRI BRAIN: 
 
HOEHN AND YAHR STAGING: 
 
 
 
 
 
 
 
 
 
 
 
 
 AUTONOMIC FUNCTION TESTS 
1.Blood Pressure   In Supine : 
   Standing : 1min 
           3 min 
2.Heart Rate Variability Ratio To Standing: 
3. Heart Rate Variability Ratio To Deep Breathing: 
4. Heart Rate Variability Ratio To Valsalva: 
5. Blood Pressure Response To Sustained Handgrip      
RestBP                                                            Test BP 
6. BP Variation To Mental Arithmetic 
RestBP                                                            Test BP 
7. BP Variation To Cold Pressor test 
RestBP                                                            Test BP 
 
 
 
  
 
Symptoms 
On standing from supine posture 
Dizziness /light headedness : 
Fainting : 
Presyncope or syncope: 
Flushing sensation: 
Dry skin: 
Excessive sweating during day or night: 
Dribbling of saliva: 
Dysphagia or food struck in mouth: 
Feeling of bloatedness: 
Constipation: 
Invouluntary  loss of stools: 
Invouluntary  loss of urine: 
Feeling of incomplete emptying: 
Frequency of micturition: 
Urgency of micturition: 
Nocturia : 
Impotence : 
Erectile dysfunction: 
Ejaculation problem: 
Failure to attain orgasm: 
 
 
 
 
  
 
 
 
ANS  Feature Yes/No Duration Onset Related 
To Disease 
Bladder 
dysfunction 
      
   
Bowel dysfunction 
   
   
Sexual 
dysfunction 
 
   
Symptoms related 
to postural 
hypotension 
   
Thermoregulatory  
dysfunction 
   
Salivation 
 
   
Cardiovascular 
dysfunction 
   
 
 
  
  
 
 
 
 
 
 
 
 
 
MASTER CHART 
MASTERCHART
ȂMALE  MOD-MODERATE   ȂURINARY    ȂNORMAL 
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ȂYES   C-CARDIAC    ȂTHERMOREGULATORY  BPȂBLOODPRESSUREHRVȂHEARTRATEVARIABILITY   ANSȂAUTONOMICNERVOUSSYSTEMH&YȂHOEHNANDYAHR
SL.NO.

AGE


SEX


ANS
DISTURBA
NCE
Y/N
DISEASE
DURATION
YEARS
TYPEOFANS
DISTURBANCE

TYPEOF
ANS
DISTUR
BANCE
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STAGING
H&Y

SEVERITY
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
BPON
MENTAL
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BPON
COLD
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BPON
POSTURE

BPON
ISOMETRIC
EXERCISE
HRVON
STANDING


HRVON
VALSALVA


HRVON
RESPIRATION


1 46 M Y 4 G 1 mild N N N N N N N 
2 48 M Y 4.5 G 1 mild N N N N N N N 
3 47 M Y 4 G 1 mild N N N N N N N 
4 49 M Y 3.5 S 1 mild N N N N N N N 
5 51 M Y 3 S 1 mild N N N N N N N 
6 52 M Y 3.5 S 1 mild N N N N N N N 
7 45 M Y 3 S 1 mild N N N N N N N 
8 47 M Y 2.5 S 1 mild N N N N N N N 
9 48 M Y 4 S 1 mild N N N N N N N 
10 45 M Y 4.5 S 1 mild N N N N N N N 
11 47 M Y 4.5 S,T U 1 mod N N N N N N N 
12 48 M Y 4 G 1 mild N N N N N N N 
13 51 M Y 4.5 S 1 mild N N N N N N N 
14 60 M Y 4 G,S 1 mild N N N N N N N 
15 46 M Y 3.5 G,S 1 mild N N N N N N N 
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16 48 M Y 3 S 1 mild N N N N N N N 
17 49 M Y 3.5 G 1 mild N N N N N N N 
18 47 M Y 3 G 1 mild N N N N N N N 
19 48 M Y 2.5 S 1 mild N N N N N N N 
20 47 M Y 4 G 1 mild N N N N N N N 
21 46 M Y 4.5 S,T U 1 mod N N N N N N N 
22 48 M Y 4.5 S,T 1 mild N N N N N N N 
23 53 M Y 6 G,T C 2 mod N N N N N AN N 
24 55 M Y 6.5 G,S,T 2 mod N N N N N N N 
25 56 M Y 7 G,S,T 2 mod N N N N N N N 
26 53 M Y 5.5 S,T C 2 mod N N N N AN N N 
27 54 M Y 6.5 G,T U 2 mod N N N N N N N 
28 56 M Y 7 T C 2 mild N N N N N N AN 
29 57 M Y 7.5 S,G,T 2 mod N N N N N N N 
30 54 M Y 7.5 S C 2 mild N N N N AN N N 
31 57 M Y 5 S,T U 2 mod N N N N N N N 
32 58 M Y 5 G U,C 2 mild N N N N N N AN 
33 52 M Y 6.5 T U,C 2 mod N N N N AN N N 
34 51 M Y 6.5 S U,C 2 mod N N N N N AN N 
35 54 M Y 5 S,G 2 mild N N N N N N N 
36 54 M Y 5.5 S,G C 2 mod N N N N AN N N 
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37 52 M Y 6.5 S,G C 2 mod N N N N N AN N 
38 58 M Y 7 T C,U 2 mod N N N N N N AN 
39 52 M Y 7.5 S C,U 2 mod N N N N AN N N 
40 51 M Y 5.5 S,G C 2 mod N N N N N N N 
41 58 M Y 6 S,G U 2 mod N N N N N N N 
42 52 M Y 7 S,G U 2 mod N N N N N N N 
43 51 M Y 7.5 S,G,T 2 mod N N N N N N N 
44 64 M Y 8.5 S,G,T C,U 3 severe AN N AN N AN AN AN 
45 65 M Y 9 S,G,T C,U 3 severe AN N AN N N AN AN 
46 64 M Y 8.5 S,G,T C,U 3 severe AN AN AN N AN AN N 
47 63 M Y 9.5 S,G,T C,U 3 severe AN N AN N AN AN AN 
48 62 M Y 10.5 S,G C 3 mod N N N AN AN N N 
49 64 M Y 9.5 S,G,T C,U 3 severe AN AN AN N AN AN N 
50 65 M Y 10 S,G,T 3 mod N N N N N N N 
51 64 M Y 9.5 S,G,T C,U 3 severe N N AN AN AN AN AN 
52 63 M Y 10 S,G C,U 3 mod N N N N AN N AN 
53 62 M Y 10.5 S,G,T C,U 3 severe AN N AN N N AN AN 
54 59 M Y 10.5 S,G C 3 mod N AN N N AN N N 
55 64 M Y 11 S,G,T C,U 3 severe N AN AN N AN AN AN 
56 68 M Y 11.5 S,G C,U 3 severe AN N AN AN AN AN AN 
57 69 M Y 10.5 S,G C,U 3 severe AN AN N AN AN AN N 
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58 70 M Y 9.5 S,G C,U 3 severe AN AN AN N AN AN AN 
59 63 M Y 10.5 S,G C,U 3 severe N AN AN AN AN AN AN 
60 64 M Y 10 S,G,T C,U 3 severe AN N AN AN AN AN AN 
61 61 M Y 10 S,G,T C,U 4 severe AN AN N AN AN AN AN 
62 65 M Y 10.5 S,G,T C,U 4 severe AN AN AN N AN AN AN 
63 62 M Y 14 S,G,T C 4 severe AN AN AN AN AN AN AN 
64 63 M Y 12 S,G,T C,U 4 severe AN AN AN AN N AN AN 
65 61 M Y 12 S,G,T C,U 4 severe AN AN AN AN AN AN AN 
66 68 M Y 12.5 S,G,T C,U 4 severe AN AN AN AN AN AN N 
67 64 M Y 10.5 S,G,T C,U 4 severe AN AN AN AN AN AN AN 
68 63 M Y 10.5 S,G,T C,U 4 severe AN AN AN AN AN AN AN 
69 63 M Y 11 S,G,T C,U 4 severe AN AN AN AN AN AN AN 
70 66 M Y 12 S,G,T C,U 4 severe AN AN AN AN AN AN AN 
71 67 M Y 10.5 S,G,T C,U 4 severe AN AN AN AN AN AN AN 
72 63 M Y 12 S,G,T C,U 4 severe AN AN AN AN AN AN AN 
73 43 M No 4 --- --- 1 NIL N N N N N N N 
74 42 M No 4.5 --- --- 1 NIL N N N N N N N 
75 41 M No 4 --- --- 1 NIL N N N N N N N 
76 40 M No 3.5 --- --- 1 NIL N N N N N N N 
77 48 M No 3 --- --- 1 NIL N N N N N N N 
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78 45 M No 3.5 --- --- 1 NIL N N N N N N N 
79 43 M No 3 --- --- 1 NIL N N N N N N N 
80 42 M No 2.5 --- --- 1 NIL N N N N N N N 
81 43 M No 4 --- --- 1 NIL N N N N N N N 
82 42 M No 5 --- --- 1 NIL N N N N N N N 
83 46 M No 6.5 --- --- 2 NIL N N N N N N N 
84 47 M No 7 --- --- 2 NIL N N N N N N N 
85 43 M No 5.5 --- --- 2 NIL N N N N N N N 
86 42 M No 6 --- --- 2 NIL N N N N N N N 
87 41 M No 9 --- --- 3 NIL N N N N N N N 
88 48 F Y 4 T 1 mild N N N N N N N 
89 49 F Y 4.5 T 1 mild N N N N N N N 
90 46 F Y 4 T U 1 mild N N N N N N N 
91 47 F Y 4 T U 1 mild N N N N N N N 
92 40 F Y 4.5 T U 1 mild N N N N N N N 
93 48 F Y 4 T U 1 mild N N N N N N N 
94 45 F Y 3.5 T U 1 mild N N N N N N N 
95 43 F Y 3 T U 1 mild N N N N N N N 
96 42 F Y 3.5 T U 1 mild N N N N N N N 
97 43 F Y 3 S,T U 1 mod N N N N N N N 
98 42 F Y 3.5 T U 1 mild N N N N N N N 
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99 46 F Y 4 T U 1 mild N N N N N N N 
100 47 F Y 4.5 S,G,T 1 mod N N N N N N N 
101 48 F Y 4 T U 1 mild N N N N N N N 
102 53 F Y 3.5 S,G,T 1 mod N N N N N N N 
103 52 F Y 3 S,G,T 1 mod N N N N N N N 
104 54 F Y 3.5 T U 1 mild N N N N N N N 
105 56 F Y 6.5 S,G,T 2 mod N N N N N N N 
106 57 F Y 7 G,T U 2 mod N N N N N N N 
107 54 F Y 6.5 S,G,T 2 mod N N N N N N N 
108 53 F Y 6.5 T C,U 2 mod N N AN N N N AN 
109 59 F Y 7 T C,U 2 mod N N N N N N N 
110 53 F Y 5.5 G,T U 2 mod N N N N N N N 
111 54 F Y 6.5 G,T U 2 mod AN N N N N N N 
112 55 F Y 7 G,T C,U 2 mod N N N N AN N N 
113 52 F Y 6.5 G,T C 2 mod N N N N N N N 
114 49 F Y 7 G C,U 2 mod N N N N N N AN 
115 51 F Y 5.5 S U 2 mild N AN N N N N N 
116 45 F Y 6.5 S,G C 2 mod N N N AN N AN N 
117 48 F Y 7 S,T C 2 mod N N N N AN N N 
118 54 F Y 5.5 G C 2 mild N AN AN N N N N 
119 58 F Y 6 S,G C,U 2 severe AN N N N AN AN AN 
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120 56 F Y 6 G C,U 2 mod N AN N AN N N N 
121 59 F Y 8 S,G C,U 3 severe AN AN N AN AN AN AN 
122 58 F Y 8.5 G C,U 3 mod N AN N N N N AN 
123 61 F Y 9 S,G C,U 3 severe AN AN AN AN AN AN AN 
124 62 F Y 9.5 S,G C,U 3 severe AN AN AN AN AN AN AN 
125 64 F Y 7.5 S,G C,U 3 severe AN AN AN AN AN AN AN 
126 70 F Y 8 S,G C,U 3 severe AN AN N AN AN AN AN 
127 63 F Y 8.5 G C,U 3 mod N AN AN AN N AN AN 
128 65 F Y 8 S,G C,U 3 severe AN AN AN AN AN AN AN 
129 64 F Y 8.5 T C,U 3 mod AN AN AN AN N AN AN 
130 63 F Y 9 G,T C,U 4 severe AN AN AN N AN AN AN 
131 63 F Y 9.5 G,T C,U 4 severe AN AN AN AN AN AN AN 
132 68 F Y 10 S,G,T C,U 4 severe AN AN AN AN AN AN AN 
133 65 F Y 10.5 S,G C,U 4 severe AN AN AN N AN AN AN 
134 46 F No 4.5 --- --- 1 NIL N N N N N N N 
135 45 F No 4 --- --- 1 NIL N N N N N N N 
136 43 F No 4.5 --- --- 1 NIL N N N N N N N 
137 54 F No 3.5 --- --- 1 NIL N N N N N N N 
138 50 F No 6.5 --- --- 2 NIL N N N N N N N 
139 46 F No 7.5 --- --- 2 NIL N N N N N N N 
140 42 F No 6 --- --- 2 NIL N N N N N N N 
141 45 F No 8.5 --- --- 3 NIL N N N N N N N 
 
